Phlegmasia cerulea dolens during the SARS-COV-2 pandemic: What management ?

Anane, Oussama; Rezziki, Abdellah; Benzirar, Adnane; Mahi, Omar El

doi:10.1016/j.amsu.2021.102541

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is the second case of PCD during the SARS-CoV-2 pandemic in our institute since the first one was published 14 . To our knowledge, Michael et al .…”

Section: Discussionmentioning

confidence: 75%

The SARS-CoV-2 responsible for phlegmasia cerulea dolens: a case report

Banana¹,

Bashir²,

Boukabous

et al. 2023

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Introduction: Coronavirus disease 2019 (COVID-19) is a worldwide pandemic systemic infection that is responsible for serious coagulopathies similar to disseminated intravascular coagulation. Case Presentation: The authors report the case of a COVID-19 patient who presented with phlegmasia cerulea dolens (PCD) of the left lower limb, so he benefited from aponeurotomies of the internal and anterolateral muscular compartments. Clinical Discussion: The severe acute respiratory syndrome coronavirus 2 involves an inflammatory process in thrombotic events in COVID-19 patients, including a cytokine storm. PCD evolves in three semiological phases: venous stasis, weakening of the pulses, and the constitution of major ischemia. In the literature, the authors find many reports that have been published regarding increased thrombus formation in COVID-19 patients; these include DVT formation, pulmonary embolism, and stroke. Nevertheless, publications concerning PCD in COVID-19 patients remain rare. Conclusion: Although the severe acute respiratory syndrome coronavirus 2 remains a thrombogenic pathology, systematic anticoagulation is the subject of hypothesis. Hence the importance of regular monitoring of markers of vascular thrombosis.

show abstract

“…This is the second case of PCD during the SARS-CoV-2 pandemic in our institute since the first one was published 14 . To our knowledge, Michael et al .…”

Section: Discussionmentioning

confidence: 75%

The SARS-CoV-2 responsible for phlegmasia cerulea dolens: a case report

Banana¹,

Bashir²,

Boukabous

et al. 2023

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

show abstract

Phlegmasia Cerulea Dolens Secondary to COVID-19 and May-Thurner Syndrome: A Case Report

Alghamdi¹,

Alattab²,

Alwohaibi³

et al. 2022

Cureus

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is associated with significant thromboembolic risk. Extensive deep vein thrombosis can infrequently progress to phlegmasia cerulea dolens that carries high morbidity and mortality rates. We report a case of a middle-aged male presenting with phlegmasia cerulea dolens in the context of COVID-19 and underlying May-Thurner syndrome, associated with transiently positive antiphospholipid antibodies.

show abstract

Phlegmasia cerulea dolens during the SARS-COV-2 pandemic: What management ?

Cited by 2 publications

References 8 publications

The SARS-CoV-2 responsible for phlegmasia cerulea dolens: a case report

The SARS-CoV-2 responsible for phlegmasia cerulea dolens: a case report

Phlegmasia Cerulea Dolens Secondary to COVID-19 and May-Thurner Syndrome: A Case Report

Contact Info

Product

Resources

About